Clinical trials: COPD
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease, Asthma
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
The first-in-man study are designed as below to assess safety, tolerability, and preliminary pharmacokinetics of ZL-2102. Double-blind randomized, placebo-controlled ascending single oral doses (Part 1, ZL-2102-SAD); Open-label…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02397005
- Testing
- ZL-2102
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zai Lab Pty. Ltd.
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients
Expiratory Flow Limitation (EFL) occurs when the airways become compressed, which usually results when the pressure outside the airway exceeds the pressure inside the airway.
- Trial name
- NCT03851510
- Testing
- Vector ventilator, Resmon Pro
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.
The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with different level of renal impairment in…
- Trial name
- TRIPLE10 (NCT02040597)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate
- Where
- 2 sites in Poland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
- Trial name
- OCEAN (NCT00628862)
- Testing
- Formoterol Turbuhaler® 4.5mg, Formoterol Turbuhaler® 9 mg
- Where
- 47 sites in Bulgaria, Japan and 3 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
- Trial name
- NCT07780669
- Testing
- GSK5784283, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- GlaxoSmithKline
COPD
Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy
This is a prospective non-interventional trial to measure the health related quality of life of patients with chronic obstructive pulmonary disease (COPD) on a fixed LAMA/LABA/ICS triple therapy (Trimbow®) and characterisation of…
- Trial name
- TriOptimize (NCT04355546)
- Testing
- Non-interventional
- Where
- United Kingdom
- Volunteers
- 94 people
- Sponsor
- Chiesi UK
Pulmonary Disease, Chronic Obstructive
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC)…
- Trial name
- NCT02182674
- Testing
- Combivent HFA, Combivent (CFC)
- Volunteers
- 66 people
- Sponsor
- Boehringer Ingelheim
COPD
Validation of a Digital Platform for Functional Respiratory Rehabilitation
Chronic Obstructive Pulmonary Disease (COPD), characterized by persistent airflow limitation in the respiratory airways, is a chronic condition that affects millions of people worldwide.
- Trial name
- ReHub (NCT06252818)
- Testing
- ReHub
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Bio-Sensing Solutions S.L. (DyCare)
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238197
- Testing
- Atrovent® Inhalation Solution
- Volunteers
- 477 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Disease, Chronic Obstructive
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo.
- Trial name
- NCT04882124
- Testing
- CSJ117
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Perception of Symptom Variability in COPD
The objective of the study is to assess patient's perception with stable state COPD on symptom variability and to describe how symptom variability impacts daily quality of life in Chinese COPD patient with moderate, severe or…
- Trial name
- NCT01753427
- Where
- 6 sites in China
- Volunteers
- 1,058 people
- Sponsor
- AstraZeneca
Stable COPD Patients
Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study
This is a multi-country, multicentre, observational prospective data collection cross sectional study of patients with stable COPD in Latin America.
- Trial name
- LASSYC (NCT02789540)
- Where
- 6 sites in Argentina, Chile and 4 more
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00801684
- Testing
- TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alkermes, Inc.
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
- Trial name
- NCT00690885
- Testing
- interferon-alpha lozenges
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
COPD, COPD Exacerbation
Clinical Feasibility of a Non-invasive Wearable Acoustic Device for Measuring Air Trapping in COPD
This is a pilot observational study during which the investigators will conduct a longitudinal assessment of air trapping (with up to 2 visits) in 40 patients with COPD and variable degrees of air trapping and 20 healthy controls…
- Trial name
- NCT04450368
- Testing
- Sylvee
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Respira Labs, Inc
Chronic Obstructive Pulmonary Disease (COPD)
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
Study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. To see which one results in the best effect on breathing.
- Trial name
- NCT04078126
- Testing
- BFF, Symbicort Turbuhaler
- Where
- 4 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca